Drug Profile
Oral controlled-release therapeutics - Otsuka Pharmaceutical/Endo Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical; Penwest Pharmaceuticals
- Developer Endo Pharmaceuticals; Otsuka Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined in USA (PO)
- 25 Jan 2010 A fourth research and development agreement has been signed between Penwest Pharmaceuticals and Otsuka Pharmaceutical
- 28 Oct 2009 A Penwest formulation completes a phase I pharmacokinetic study